(ALGS) Aligos Therapeutics - Overview
Stock: Capsid Modulator, siRNA, THR-β Agonist, Protease Inhibitor
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 109% |
| Relative Tail Risk | -14.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.78 |
| Alpha | -102.03 |
| Character TTM | |
|---|---|
| Beta | 2.325 |
| Beta Downside | 2.995 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.25% |
| CAGR/Max DD | -0.47 |
Description: ALGS Aligos Therapeutics December 22, 2025
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharma focused on novel small-molecule, capsid-assembly, and siRNA therapeutics targeting viral infections and metabolic liver disease, primarily non-alcoholic steatohepatitis (NASH) and chronic hepatitis B (CHB).
The lead candidate, ALG-055009, is a thyroid-hormone-receptor-β (THR-β) agonist currently in a Phase 2a trial for NASH, a disease with an estimated $30 billion addressable market in the United States by 2028. The company’s CHB pipeline includes ALG-000184 (capsid assembly modulator, completed Phase 1b) and ALG-125755 (siRNA, in Phase I), while ALG-097558 is in Phase 2 for a coronavirus protease inhibitor.
Aligos has secured multiple external partnerships: a discovery and development agreement with Merck for NASH-targeted oligonucleotides; licensing deals with Emory University, Luxna Biotech, and KU Leuven for HBV capsid modulators and coronavirus protease inhibitors; and a clinical collaboration with Xiamen Amoytop Biotech. These collaborations provide both non-dilutive funding and validation of its platform technology.
From a financial perspective, the firm reported a cash runway of roughly 12 months as of Q3 2024 and a cash-burn rate of about $15 million per quarter, reflecting typical R&D intensity for early-stage biotech. The broader biotech sector is experiencing an 8 % YoY increase in R&D spend, driven by heightened investor appetite for gene-editing and RNA-based therapeutics, which could benefit Aligos if its pipeline advances.
For a deeper quantitative view, you may want to explore ValueRay’s analyst dashboard.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -86.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.72 > 0.02 and ΔFCF/TA 23.79 > 1.0 |
| NWC/Revenue: 3078 % < 20% (prev 981.6%; Δ 2097 % < -1%) |
| CFO/TA -0.72 > 3% & CFO -79.2m > Net Income -86.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (10.4m) vs 12m ago 65.32% < -2% |
| Gross Margin: 64.85% > 18% (prev 0.66%; Δ 6420 % > 0.5%) |
| Asset Turnover: 2.67% > 50% (prev 6.78%; Δ -4.11% > 0%) |
| Interest Coverage Ratio: -106.8 > 6 (EBITDA TTM -84.8m / Interest Expense TTM -814.0k) |
Altman Z'' -15.00
| A: 0.74 (Total Current Assets 103.4m - Total Current Liabilities 22.0m) / Total Assets 109.8m |
| B: -5.67 (Retained Earnings -622.3m / Total Assets 109.8m) |
| C: -0.88 (EBIT TTM -87.0m / Avg Total Assets 99.1m) |
| D: -16.39 (Book Value of Equity -621.9m / Total Liabilities 37.9m) |
| Altman-Z'' Score: -36.73 = D |
What is the price of ALGS shares?
Over the past week, the price has changed by -9.29%, over one month by -16.44%, over three months by +3.10% and over the past year by -73.38%.
Is ALGS a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ALGS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.2 | 831.7% |
| Analysts Target Price | 68.2 | 831.7% |
| ValueRay Target Price | 5 | -31.4% |
ALGS Fundamental Data Overview February 04, 2026
P/B = 0.6952
Revenue TTM = 2.65m USD
EBIT TTM = -87.0m USD
EBITDA TTM = -84.8m USD
Long Term Debt = 6.07m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.56m USD (from shortTermDebt, last quarter)
Debt = 6.07m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -35.9m USD (from netDebt column, last quarter)
Enterprise Value = -44.1m USD (48.9m + Debt 6.07m - CCE 99.1m)
Interest Coverage Ratio = -106.8 (Ebit TTM -87.0m / Interest Expense TTM -814.0k)
EV/FCF = 0.55x (Enterprise Value -44.1m / FCF TTM -79.5m)
FCF Yield = 180.3% (FCF TTM -79.5m / Enterprise Value -44.1m)
FCF Margin = -3006 % (FCF TTM -79.5m / Revenue TTM 2.65m)
Net Margin = -3268 % (Net Income TTM -86.5m / Revenue TTM 2.65m)
Gross Margin = 64.85% ((Revenue TTM 2.65m - Cost of Revenue TTM 930.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev 73.16%)
Tobins Q-Ratio = -0.40 (set to none) (Enterprise Value -44.1m / Total Assets 109.8m)
Interest Expense / Debt = 210.9% (Interest Expense 12.8m / Debt 6.07m)
Taxrate = 21.0% (US default 21%)
NOPAT = -68.7m (EBIT -87.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.70 (Total Current Assets 103.4m / Total Current Liabilities 22.0m)
Debt / Equity = 0.08 (Debt 6.07m / totalStockholderEquity, last quarter 71.8m)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -35.9m / EBITDA -84.8m)
Debt / FCF = 0.45 (negative FCF - burning cash) (Net Debt -35.9m / FCF TTM -79.5m)
Total Stockholder Equity = 65.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -87.25% (Net Income -86.5m / Total Assets 109.8m)
RoE = -132.4% (Net Income TTM -86.5m / Total Stockholder Equity 65.3m)
RoCE = -121.9% (out of range, set to none) (EBIT -87.0m / Capital Employed (Equity 65.3m + L.T.Debt 6.07m))
RoIC = -105.2% (out of range, set to none) (NOPAT -68.7m / Invested Capital 65.3m)
WACC = 12.88% (E(48.9m)/V(55.0m) * Re(14.48%) + (debt cost/tax rate unavailable))
Discount Rate = 14.48% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -9.54%
Fair Price DCF = unknown (Cash Flow -79.5m)
EPS Correlation: -52.87 | EPS CAGR: -5.01% | SUE: -0.83 | # QB: 0
Revenue Correlation: -48.97 | Revenue CAGR: 20.61% | SUE: 0.75 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-2.42 | Chg30d=-0.324 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-7.11 | Chg30d=+0.099 | Revisions Net=+1 | Growth EPS=+6.3% | Growth Revenue=-13.2%